ADAM17 and non-small cell lung carcinoma: It also plays a role in non-small cell lung carcinoma (NSCLC), as silencing ADAM17 expression via siRNA can inhibit tumour cell proliferation and invasion in vitro, as well as tumour growth in vivo [102].